证券研究报告 2025 年 12 月 14 日 湘财证券研究所 行业研究 证券行业周报 市场交投保持活跃，关注券商估值修复机会 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -3 -8 -20 绝对收益 -4 -5 -3 -30% -20% -10% 0% 10% 20% 2024/12/12 2025/2/12 2025/4/12 2025/6/12 2025/8/12 2025/10/12 2025/12/12 沪深300 证券Ⅱ(申万) 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： ❑ 市场回顾：本周券商指数跑赢沪深 300，头部大型券商领涨 相关研究： | 1.《行业周报：券商估值持续回落， | | --- | | 关注配置价值》 2025.12.7 | 根据 Wind 数据，本周（12.8-12.12）上证指数下跌 0.3%，沪深 300 指数下 跌 0.1% ...

证券研究报告 2025 年 12 月 14 日 湘财证券研究所 金融工程研究 跟踪周报 超预期股票精选策略跟踪周报 相关研究： 1. 《湘财证券-金融工程-超预期股 票精选策略》 2024.08.19 2. 《湘财证券-金融工程-超预期股 票 精 选 策 略 改 进 》 2024.11.19 分析师：别璐莎 证书编号：S0500524010001 Tel：(021) 50293663 Email：bls06644 @xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 核心要点： ❑ 主动型量化基金市场表现 本周（2025.12.08-2025.12.12），根据 Wind，主动型量化基金中位数收益为 -0.10%，沪深 300 指数收益为-0.08%，Wind 全 A 指数收益为 0.26%；本年， 主动型量化基金中位数收益为 26.41%，沪深 300 指数收益为 16.42%，Wind 全 A 指数收益为 24.80%。 本周，根据 Wind，收益排名靠前的主动型量化基金的收益率在 6%至 11% 之间，基金的重仓行业集中在电子行业；收益排名靠后的主动型量化基金 的收益率在-5%至 ...

证券研究报告 2025 年 12 月 14 日 湘财证券研究所 行业研究 家电行业周报 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -1.4% 8.1% 9.7% 绝对收益 -1.5% 17.7% 17.1% 内需主导，国补政策延续 相关研究： | 1.《估值洼地，龙头业绩确定性 | | | --- | --- | | 强》 | 2025.12.01 | | 2.《铜登凌云处，上游觅新机》 | | | 2025.12.07 | | 注：相对收益与沪深 300 相比 分析师：李育文 证书编号：S0500523060001 Tel：021-50295328 Email：liyw3@xcsc.com 根据 ifind，本周家用电器行业涨跌幅为-1.98%，在申万同行业中排名第 25 位，同期沪深 300 指数涨跌幅-0.08%。子板块中，其他黑色家电（+1.29%）、 家电零部件Ⅲ（-0.54%）、冰洗（-1.84%）三个子行业在本行业涨幅靠前。 ❑ 估值低位，国补延续打开上行空间 估值历史低位，具备上涨空间。根据 ifind，以 PE-ttm 口径（整体法，剔除 负值 ...

证券研究报告 2025 年 12 月 14 日 湘财证券研究所 行业研究 房地产行业周报 相关研究： 核心要点： ❑ 核心城市：核心城市二手房成交在高基数影响下大幅下滑 1.《周度观点：11月一线城市新房 销售降幅较大》 2025.11.23 行业评级：买入（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 -25% -15% -5% 5% 15% 沪深300 房地产(申万) | % | 1 个月 | 3 个月 | 12 个月 | | --- | --- | --- | --- | | 相对收益 | -7 | -8 | -27 | | 绝对收益 | -8 | -6 | -13 | 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 成交下行压力加大，关注后续政策落地 ❑ 投资建议 由于四季度核心城市的新房、二手房成交基数较高，叠加今年政策影响较 为温和，因此 10 月以来新房、二手房成交同比持续下行，有待进一步出台 政策稳定楼市。近期召开的中央经济工作会议明确了明年的房地产 ...

证券研究报告 2025 年 12 月 13 日 湘财证券研究所 金融工程研究 基金研究 ETF 市场跟踪与配置周报 根据 Wind 数据，按照基金上市日，本周共有 4 只 ETF 新上市，均为股票 型 ETF，包括景顺长城中证科创创业人工智能 ETF（159142.OF）和永赢中 证科创创业人工智能 ETF（159141.OF）两只科创创业 AIETF、博时中证银 行 ETF（159253.OF）和东财中证港股通科技 ETF（520530.OF）；按照基 金成立日，本周共有 6 只 ETF 新成立，包括华泰柏瑞中证科创创业人工智 能 ETF（159139.OF）等 2 只人工智能 ETF、广发上证科创板芯片设计主题 ETF（589210.OF）和广发中证全指食品 ETF（563850.OF）等其他 2 只 ETF， 总发行规模为 29.01 亿元。 根据 Wind 数据，本周股票型 ETF 周涨跌幅中位数为 0.10%。通信设备 ETF 与创业板人工智能 ETF 表现相对较好，涨幅较为靠前，其中通信设备 ETF 涨幅最多，上涨 7.30%；而煤炭 ETF 和能源 ETF 表现相对较差，跌幅较为 靠前，其中煤炭 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry [7] Core Insights - The medical and biological sector experienced a decline of 1.04% this week, ranking 17th among 31 primary industries [15] - The medical services sub-sector reported a closing value of 6239.94 points, with an increase of 1.67% [28] - The report highlights a shift in policy focus from cost control to quality and efficiency in the medical sector, emphasizing the need for innovation and sustainable practices [4][70] Summary by Sections Industry Performance - The medical services sector's PE (ttm) is 31.74X, with a PB (lf) of 3.20X, showing a slight decrease from the previous week [3][36] - The top-performing companies in the medical services sector include Zhaoyan New Drug (+23.4%) and MediWest (+12.5%), while the underperformers include Guangzheng Eye Hospital (-9.4%) and Lanwei Medical (-8.7%) [2][34] Economic Policy Developments - The Central Economic Work Conference emphasized optimizing drug procurement and deepening medical insurance payment reforms, aiming to enhance the quality and efficiency of the medical industry [4][70] - The introduction of a long-term care insurance system is expected to stimulate the rehabilitation care industry and address aging population needs [11][72] Investment Recommendations - The report suggests focusing on high-growth areas such as ADC CDMO and the weight-loss drug supply chain, with specific companies like WuXi AppTec and Haoyuan Pharmaceutical highlighted [13][74] - It also points to potential recovery in profitability for third-party medical testing laboratories and consumer healthcare sectors, particularly in ophthalmology and dentistry [13][75]

晨 会 纪 要 [2025]第 228 号 主 题：公司深度报告汇报 时 间：2025 年 12 月 12 日 8:50-9:30 会议形式：腾讯会议 参会人员：曹旭特 仇华 许雯 王攀 蒋栋 轩鹏程 文正平 李杰 张智珑 郭怡萍 李育文 李正威 别璐莎 邢维洁 马丽明 贺钰偲 汪炜 聂孟依 张弛 整理记录：张弛 研究所今日晨会要点如下: 一、行业公司 1、公司深度——燕京啤酒首次覆盖报告（张弛） 人员变革让燕啤这家老国企焕发新生 昨日的燕啤：曾经辉煌，暂时落后。燕京啤酒是中国五大啤酒集团中唯一没有外资背 景的民族企业，母公司为燕啤投资，实控人为北京国资委下属的北控集团。公司自 80 年 代成立以来不断发展，但 2014 年后随行业一起陷入低谷，存在体制僵化、转型迟缓、收 入下滑等问题，发展滞后于同业。 今日的燕啤：人员调整，改革提速。20-22 年期间公司管理团队发生较大变化，耿超 为核心的新任领导班子推行大刀阔斧的改革，帮助公司自 21 年起利润年年创新高，股价 显著跑出超额收益。 行业现状 价格端持续上涨，瓶快于罐，主流价格带仍低。燕啤自身吨价不高，且扎实做好大众 档到次高档的消费升级，在本周期内表现强 ...

Industry Overview - The medical and health industry is experiencing stable development, but the willingness to pay needs to be considered under aging demographics [5] - Last week, the pharmaceutical and biological sector declined by 0.74%, ranking 21st among 31 primary industries [2] - The medical service sector's PE (ttm) is 31.14X, with a PB (lf) of 3.14X, showing a slight decrease from the previous week [3][4] Key Data Points - The medical service sector's PE decreased by 0.48X and PB decreased by 0.04X compared to the previous week [4] - According to the National Health Commission, the average life expectancy in China reached 79 years, with maternal mortality at 14.3 per 100,000 and infant mortality at 4.0 per thousand [5] - Medical expenses as a percentage of GDP decreased by 0.3 percentage points, with government spending on healthcare dropping by 6.4% [5] Market Insights - The aging population is increasing medical demand, but there is a need to consider the willingness to pay [6] - The medical service sector is expected to see opportunities for leading companies like Aier Eye Hospital due to the rising barriers for new entrants [6] - The innovative pharmaceutical chain is likely to benefit companies focusing on breakthrough drugs, such as WuXi AppTec and Haoyuan Pharmaceutical [6] Investment Recommendations - Despite recent market volatility, the medical industry is expected to stabilize due to the establishment of a multi-tiered payment system [7] - Investment focus should be on high-growth areas such as ADC CDMO and weight-loss drug supply chains, with companies like WuXi AppTec and Haoyuan Pharmaceutical recommended [7] - Companies in the third-party testing laboratory sector and consumer healthcare, particularly in ophthalmology and dentistry, are also suggested for investment [8]

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - The report highlights the potential investment opportunities in edge AI, particularly with the release of the "Doubao Mobile Assistant" by ByteDance, which showcases the capabilities of AI in mobile applications [5][6] - The electronic industry has shown a recovery trend in consumer electronics, with continuous releases of foldable smartphones and sustained high demand for AI infrastructure [19] Market Performance - The electronic industry index rose by 1.09% during the week of December 1 to December 5, 2025, closing at 6300.64 points [3][10] - The semiconductor sector reported a slight increase of 0.88%, while consumer electronics saw a rise of 1.61% [3] - Year-to-date, the electronic industry index has increased by 42.15%, outperforming the CSI 300 by 25.65 percentage points [10] Valuation Metrics - The electronic sector's Price-to-Earnings (PE) ratio (TTM, excluding negative values) is 57.70X, which is at the 39.97th percentile of the past 10 years [4][11] - The Price-to-Book (PB) ratio is 4.81X, positioned at the 57.57th percentile historically [4][11] Industry Dynamics - The report emphasizes the collaboration between Doubao and smartphone manufacturers to integrate AI capabilities into mobile operating systems, enhancing user experience through complex task automation [5][6] - The ongoing advancements in AI technology are expected to drive demand for edge hardware upgrades, particularly in sectors like SOC and thermal materials [19] Investment Recommendations - The report suggests focusing on investment opportunities in AI infrastructure, edge SOC, the supply chain for foldable smartphones, and the storage industry [19] - Specific companies to watch in the AI infrastructure sector include Cambricon, Chipone, and Aowei Technology, while in the edge SOC sector, companies like Rockchip, Hengxuan Technology, and Espressif Systems are recommended [19]

Investment Rating - The industry investment rating is maintained at "Overweight" [3][8] Core Insights - The medical consumables sector experienced a decline of 0.89% last week, with the sector's performance lagging behind the CSI 300 index by 2.02 percentage points [5][10] - The current PE ratio for the medical consumables sector is 35.43X, showing a week-on-week decrease of 0.36 percentage points, while the PB ratio stands at 2.54X [6][19] - Recent approvals for innovative products in the high-value consumables segment are expected to provide new growth points for companies, alongside ongoing performance recovery from previous procurement pressures [7][24] Summary by Sections Industry Performance - The medical consumables sector reported a relative return of -2% over the past month, -11% over three months, and -12% over the past year, with an absolute return of -1% over the past month, -6% over three months, and +4% over the past year [4][10] Valuation Metrics - The PE ratio for the medical consumables sector is currently at 35.43X, with a maximum of 40.1X and a minimum of 28.88X over the past year. The PB ratio is at 2.54X, with a maximum of 2.92X and a minimum of 2.13X during the same period [6][19] Industry Dynamics and Company Announcements - Recent product approvals include a disposable pressure monitoring catheter for cardiac pulsed field ablation by Shanghai Micro-Invasive Electrophysiology Medical Technology Co., Ltd., enhancing treatment options for arrhythmias [7][20] - Beijing Bairen Medical Technology Co., Ltd. received approval for its ePTFE membrane product, which addresses a significant domestic market need for cardiac surgeries, previously reliant on imports [7][21] Investment Recommendations - The report suggests focusing on leading companies with rich product lines and high innovation levels in high-value consumables, such as Micro-Invasive Electrophysiology and Maipu Medical, as well as orthopedic consumables companies showing marginal performance improvement, like Weigao Orthopedics [8][24]